Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Centene Corporation recently reported its financial outcomes for the first quarter of 2025, detailing both its present achievements and future expectations.</li><li>The highlights of their performance reveal a complex interplay of growth prospects and operational challenges within the different segments it operates.</li><li>For the first quarter, Centene achieved an adjusted diluted EPS of $2.90, aligning with prior forecasts.</li></ul>

Centene Corporation recently reported its financial outcomes for the first quarter of 2025, detailing both its present achievements and future expectations.The highlights of their performance reveal a complex interplay of growth prospects and operational challenges within the different segments it operates.For the first quarter, Centene achieved an adjusted diluted EPS of $2.90, aligning with prior forecasts.

Centene Corporation: Leveraging Clinical Initiatives & Operating Models To Change The Game!

<ul><li>Centene Corporation's recent performance exhibited both strengths and areas for careful attention.</li><li>The company's financial results for the fourth quarter of 2024 demonstrated solid earnings power, with adjusted diluted earnings per share (EPS) of $0.80 and a full-year EPS of $7.17.</li><li>This growth is attributed to robust performance across its business lines, including Medicare and Medicaid, and significant operational improvements.</li></ul>

Centene Corporation's recent performance exhibited both strengths and areas for careful attention.The company's financial results for the fourth quarter of 2024 demonstrated solid earnings power, with adjusted diluted earnings per share (EPS) of $0.80 and a full-year EPS of $7.17.This growth is attributed to robust performance across its business lines, including Medicare and Medicaid, and significant operational improvements.

Centene Corporation: Medicare Segment Growth Driving Our Bullishness!

<ul><li>Centene Corporation has reported its third-quarter financial results for 2024, showcasing a nuanced performance that reflects both strengths and ongoing challenges within its operations.</li><li>The company achieved an adjusted diluted EPS of $1.62, which exceeded prior expectations.</li><li>This outperformance was partly due to tax benefits projected for later in the year being realized earlier, as well as some accelerated income tax benefits.</li></ul>

Centene Corporation has reported its third-quarter financial results for 2024, showcasing a nuanced performance that reflects both strengths and ongoing challenges within its operations.The company achieved an adjusted diluted EPS of $1.62, which exceeded prior expectations.This outperformance was partly due to tax benefits projected for later in the year being realized earlier, as well as some accelerated income tax benefits.

Centene Corporation: Operational Efficiency & AI Utilization Driving Our Optimism! - Major Drivers

Cross-Asset Strategist & Quantitative Analyst, Pennock Idea Hub

Cam Hui

Cross-Asset Strategist & Quantitative Analyst

Pennock Idea Hub

We are creators of independent equity research. The Pennock Idea Hub team are veterans of the investment industry. Much of our team has spent their careers at Merrill Lynch, Deutsche Bank, RBC Capital Markets and Wood Gundy. We have taken every aspect of research back to the studs and returned to first principles. The Pennock Idea Hub marries the interests of the sell and buy side. 

We offer the best research for institutional investors by:

-Only publishing research from veteran analysts
-Eliminate the inherent conflicts of the traditional sell and buy side relationship
-Ensure our team is always accessible; collaboration with clients nurtures our collective success

Cross-Asset & Quantitative Research

Cross Asset Strategy

<ul>
<li>The stock market is likely to advance during the Santa Claus rally window, which began on December 24 and ends January 3.</li>
<li>But the rally is attributed to an oversold bounce and marked by narrow leadership. Either the rebound fizzles in January or broadens into lagging issues.</li>
<li>We identified selected contrarian value opportunities for bulls among Santa’s discards for potential outperformance into January and beyond.</li>
</ul>


The stock market is likely to advance during the Santa Claus rally window, which began on December 24 and ends January 3.
But the rally is attributed to an oversold bounce and marked by narrow leadership. Either the rebound fizzles in January or broadens into lagging issues.
We identified selected contrarian value opportunities for bulls among Santa’s discards for potential outperformance into January and beyond.


Contrarian Bargains Among Santa's Discards

<ul><li>Centene Corporation has provided an encouraging financial performance in its first quarter of the year, as echoed in their latest review of modified earnings and strategic developments across various business units.</li><li>Notably, the company exceeded their expected adjusted earnings per share (EPS) at $2.26, prompting an upward revision in their full-year 2024 forecast to over $6.80 per share.</li><li>While these results show solid progress and operational efficiency, they frame a nuanced picture—detailing areas of strength alongside ongoing challenges.</li></ul>

Centene Corporation has provided an encouraging financial performance in its first quarter of the year, as echoed in their latest review of modified earnings and strategic developments across various business units.Notably, the company exceeded their expected adjusted earnings per share (EPS) at $2.26, prompting an upward revision in their full-year 2024 forecast to over $6.80 per share.While these results show solid progress and operational efficiency, they frame a nuanced picture—detailing areas of strength alongside ongoing challenges.

Centene Corporation: Medicaid Managed Care Expansion and Optimization! - Major Drivers

United States

Centene Corporation is a multi-line managed care organization that provides Medicaid and Medicaid-related programs.  The Company has health plans in several states. The Company also provides specialty services, including behavioral health, nurse triage, and treatment compliance.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Centene Corp (CNC US)

Centene Corporation: Leveraging Clinical Initiatives & Operating Models To Change The Game!

Centene Corporation recently reported its financial outcomes for the first quarter of 2025, detailing both its present achievements and future...

Baptista Research

Centene Corporation: Medicare Segment Growth Driving Our Bullishness!

Centene Corporation's recent performance exhibited both strengths and areas for careful attention. The company's financial results for the fourth...

Baptista Research

Centene Corporation: Operational Efficiency & AI Utilization Driving Our Optimism! - Major Drivers

Centene Corporation has reported its third-quarter financial results for 2024, showcasing a nuanced performance that reflects both strengths and...

Baptista Research

Contrarian Bargains Among Santa's Discards

We identified selected contrarian value opportunities for bulls among Santa’s discards for potential outperformance into January and beyond.

Cam Hui

Centene Corporation: Medicaid Managed Care Expansion and Optimization! - Major Drivers

Centene Corporation has provided an encouraging financial performance in its first quarter of the year, as echoed in their latest review of...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)